Search This Blog

Saturday, October 30, 2021

Colorado lawsuit tests bounds of religious exemptions to COVID vaccines

 This is a true story about heroes and villains in the age of coronavirus and how no one can agree on who is which.

The doctor, one of the protagonists of this story, is a pediatric intensive care specialist in Colorado Springs working with some of the sickest children in the state. She’s unvaccinated against COVID-19, despite both state and employer mandates requiring vaccination.

In one telling of this tale, the doctor is the hero, a devoutly religious person who has made a moral choice consistent with those beliefs and is being unconstitutionally punished for them. In another telling, the doctor is the villain, using her religion as cover for a personal belief that is recklessly endangering her patients and colleagues.

Both versions of the story are contained within the pleadings of an ongoing lawsuit in federal court in Denver that challenges the University of Colorado Anschutz Medical Campus’s vaccination requirement for physicians and medical students. Which version is the right one will be the subject of a complicated  — and closely watched — legal analysis where the outcome is unclear and the arguments have veered into philosophical debates over the very nature of the country.

“In a religiously pluralistic society, we have to respect people’s religious objections,” said Peter Breen, an attorney representing the doctor and her co-plaintiff, a medical student at the University of Colorado School of Medicine.

CU responded in court by quoting from an 1878 U.S. Supreme Court decision: “To permit this would be to make the professed doctrines of religious belief superior to the law of the land, and in effect to permit every citizen to become a law unto himself.”

Ultimately, the Supreme Court could decide again. But beyond the courtroom battle, the case shows the difficulty Colorado hospitals and other health care organizations have faced in sorting out what is a valid religious exemption to the COVID vaccine mandate, what is not and whether they should be making that decision at all.

“The standard for a sincerely held religious belief is so general, it’s open to different kinds of arguments,” said Christopher Jackson, a Denver-based attorney who specializes in constitutional and appellate law.

Doe v. CU

The two plaintiffs in the federal lawsuit against CU are anonymous — they go by Dr. Jane Doe and John Doe in the court documents.

Both say that requiring them to take a coronavirus vaccine conflicts with their religious beliefs. The doctor, who is Catholic, and the medical student, who is Buddhist, say they are opposed to the use of cell lines that were derived from cells taken decades ago from aborted fetuses. The plaintiffs say the cell lines, which are frequently used in medical research, were used in either the production or testing of the three coronavirus vaccines currently approved in the United States. 

The student also says he has a religious objection to vaccination in general.

Officials on the University of Colorado’s Anschutz Medical Campus denied their requests for a religious exemption. In court filings, the university questions whether the plaintiffs’ religious objections are sincere, noting that the student has received at least once vaccine previously and that the doctor regularly prescribes medicines that were tested using the same cell lines.

“Plaintiffs’ failure to raise prior objections to vaccinations and medications demonstrates that their professed religious objection to these vaccines is not a ‘sincerely held belief,’ but rather a personal, or perhaps a political, choice,” the university wrote in one case filing.

CU also notes that major leaders of the plaintiffs’ religions — including, in the case of Catholicism, the pope — have spoken in favor of vaccination against COVID.

“Dr. Doe … did not articulate an individualized Catholic belief different from the views of the Vatican doctrinal office or the U.S. Conference of Catholic Bishops, which have come out strongly in favor of vaccination against COVID-19,” CU wrote in the filing.

But, to Breen, this is offensive. He said the university’s initial policy on vaccine religious exemptions was “flagrantly religiously bigoted” and that the CU Anscutz campus may be the worst in the country for accomodating religious objection to vaccination.

“I’ve never seen a case where a government has been so vicious in attacking what are clearly sincere religious beliefs,” said Breen, who is the senior counsel for the Thomas More Society, an organization that often takes on religious liberty cases.

But, even more than its legal tactics, Breen said CU has violated an important provision of the constitutional separation of church and state.

The doctor, Breen said, has a master’s degree in Catholic bioethics. And Catholic viewpoints on the COVID vaccines are varied. Breen noted that some Catholic leaders — including those in Colorado — have come out against mandates for the coronavirus vaccine, saying that Catholic teaching stresses the importance of honoring individual conscience.

The Colorado Catholic Conference has published on its website a template for requesting a vaccine religious exemption.

“The people of Colorado should be outraged that their government is getting into the nuances of Catholic theology and trying to tell individual Catholics what they do and don’t believe,” Breen said.

To CU, though, these debates are missing an equally important point: the stakes involved. More than 8,000 people have now died due to COVID-19 in Colorado. The purpose of the vaccine mandate isn’t to trample religious belief but to protect patients, it says.

The university said in a court filing that the plaintiffs’ arguments contain “barely a mention of the magnitude of the COVID crisis and the risk their refusal to be vaccinated presents to the most vulnerable.”

In a statement, the university said: “Each year, School of Medicine faculty members provide care for more than 2 million patients and our mandatory vaccination requirement offers the best way to protect the patients in their care. We have adopted this policy in recognition of our responsibility to provide public health leadership in our state and beyond.”

The first major decision in the lawsuit came down Monday, when U.S. District Court Judge Raymond P. Moore denied the plaintiffs’ request for a preliminary injunction against CU. But he did so for a technical reason — the policy on religious exemptions that the plaintiffs were trying to stop CU from enforcing has since been rescinded and replaced with a new policy.

Breen said his side may soon be adding more plaintiffs and amending the lawsuit to include more challenges to the new policy.

Jackson, the constitutional law attorney, said courts have generally tried to stay out of fights over religious exemptions. As long as an employer’s policy is one of “general applicability” — that is, as long as it applies to everyone equally and doesn’t single out one religion — then it usually passes muster.

“Under the current law as it stands, these kinds of cases are relatively easy,” Jackson said.

But the makeup of the current U.S. Supreme Court — conservative-leaning with multiple justices who often rule in favor of religious liberty claims — throws that into question.

Guidance for handling religious vaccine exemptions continues to confound, as well.

On Monday, the U.S. Equal Employment Opportunity Commission released new “technical assistance” for employers instituting COVID vaccine mandates.

The guidance says employers “should assume that a request for religious accommodation is based on sincerely held religious beliefs” but also says that employers may “be justified in making a limited factual inquiry and seeking additional supporting information” about the sincerity of an employee’s beliefs. Employers should accommodate non-traditional religious beliefs but not beliefs that are personal or political.

Employers can deny exemption to employees who have previously acted inconsistently with their beliefs but employees “need not be scrupulous in their observance” in order to receive religious protection.

“No one factor or consideration is determinative,” the EEOC wrote, “and employers should evaluate religious objections on an individual basis.”

Ultimately, how officials decide which religious exemptions are valid and which are not could have a huge impact on Colorado’s health care system.

In addition to a number of mandates by employers, such as the CU School of Medicine’s, Colorado’s Board of Health has also issued a COVID vaccine mandate for health care workers. Hospitals, nursing homes and other facilities are required to have 100% compliance.

But, faced with imminent staff shortages if unvaccinated workers had to leave their jobs, health care facilities across the state have allowed employees to claim religious exemptions to the COVID vaccine mandate.

There’s a catch, though. The state’s current mandate considers employees who are claiming such an exemption to not be in compliance with the order, meaning their facilities can’t reach the required 100% vaccination rate.

This means those facilities must ask the Colorado Department of Public Health and Environment with a waiver from the mandate. State regulators have received more than 900 waiver applications, each of which they are currently reviewing.

Jill Hunsaker Ryan, executive director of the Colorado Department of Public Health and Environment, makes a point during a news conference Wednesday, July 7, 2021, to introduce the fifth and final $1-million winner in the state’s vaccine lottery at the governor’s mansion in Denver. (AP Photo/David Zalubowski)

In a letter sent earlier this month, CDPHE Executive Director Jill Hunsaker Ryan wrote that her agency would consider a facility’s number of employees claiming an exemption when deciding whether to approve a waiver. Rural hospitals, especially, have raised concerns about what would happen if CDPHE takes a hard line on religious exemptions. CDPHE, meanwhile, has not announced publicly how deeply it will dig to determine if a religious exemption is valid.

CDPHE has said it plans to amend its mandate in the coming months to better align with a federal mandate for health care workers, the rules of which have not yet been finalized.

That leaves much unknown about the future of Colorado’s vaccine mandates for health care workers — and about how, in a polarized time when religious belief and personal belief and political belief overlap and merge, the state will determine who is the hero and who is the villain. 

“It’s difficult to do,” said Jackson. “It’s very difficult to look into someone’s mind.”

https://coloradosun.com/2021/10/27/coronavirus-vaccine-mandate-religious-exemption/

White House suggests flexibility on vaccine mandate

The White House’s coronavirus response coordinator indicated that the Biden administration could be flexible as it enforces the president’s executive order requiring federal workers and employees of government contractors to be vaccinated.

“To be clear, we’re creating flexibility within the system. We’re offering people multiple opportunities to get vaccinated. There is not a cliff here,” Jeff Zients said. 

https://www.washingtonpost.com/nation/2021/10/28/covid-delta-variant-live-updates/

US intel doesn't expect to find virus origin

 Barring an unforeseen breakthrough, intelligence agencies will not be able to conclude whether COVID-19 spread by animal-to-human transmission or leaked from a lab, US officials say in releasing a fuller version of their review into the origins of the pandemic.

The paper issued by the Director of National Intelligence elaborates on findings released in August of a 90-day review ordered by US President Joe Biden.

That review said that US intelligence agencies were divided on the origins of the virus but that analysts do not believe the virus was developed as a bioweapon and that most agencies believe the virus was not genetically engineered.

China has resisted global pressure to co-operate fully with investigations into the pandemic or provide access to genetic sequences of coronaviruses kept at the Wuhan Institute of Virology, which remains a subject of speculation for its research and reported safety problems.

Biden launched the review amid growing momentum for the theory - initially broadly dismissed by experts - that the virus leaked from the Wuhan lab.

Former president Donald Trump and his allies long argued that a lab leak was possible.

China remains an exceedingly difficult place for intelligence operations and has fought back against allegations that it mishandled the emergence of the pandemic, which has killed almost five million people worldwide.

Senior officials involved in the full report's drafting said they hoped it would better inform the public about the challenges of determining COVID-19's origins.

"We don't think we're one or two reports away from being able to understand it," said one official, who spoke on condition of anonymity to discuss intelligence matters.

The full report notes that the Wuhan Institute of Virology "previously created chimeras, or combinations, of SARS-like coronaviruses, but this information does not provide insight into whether SARS Cov-2 was genetically engineered by the WIV".

Information that lab researchers sought medical treatment for a respiratory illness in November 2019 "is not diagnostic of the pandemic's origins," the report said.

And allegations that China launched the virus as a bioweapon were dismissed because their proponents "do not have direct access to the Wuhan Institute of Virology," are making scientifically invalid claims or are accused of spreading disinformation, the report said.

Four agencies within the intelligence community said with low confidence that the virus was initially transmitted from an animal to a human.

A fifth intelligence agency believed with moderate confidence that the first human infection was linked to a lab.

Prior to writing the report, analysts conducted what the report describes as a "Team A/Team B" debate to try to strengthen or weaken each hypothesis.

Confirming with 100 per cent certainty the origin of a virus is often not fast, easy or always even possible.

In the case of Severe Acute Respiratory Syndrome, or SARS - a disease caused by a beta coronavirus, like the current coronavirus - researchers first identified the virus in February 2003.

Later that year, scientists discovered the likely intermediary hosts: Himalayan palm civets found at live-animal markets in Guangdong, China.

But it was not until 2017 that researchers traced the likely original source of the virus to bat caves in China's Yunnan province.

https://www.perthnow.com.au/news/coronavirus/us-spies-dont-expect-to-find-virus-origin-c-4369756

COVID Vaccine Makers Prepare for Variant Worse Than Delta

 Pfizer’s chief executive, Albert Bourla, made a bold promise in June. Standing next to US President Joe Biden at a press conference in St Ives, UK, just before the G7 summit meeting, Bourla said that should the need arise for a new COVID-19 vaccine, his company could get one ready within 100 days.

The need he was referring to is the possible emergence of an ‘escape variant’ — a dominant strain of SARS-CoV-2 that evades the fledgling immunity established through vaccines and previous infections. No such strain has yet been identified, but Pfizer and other leading COVID-19 vaccine makers are gearing up for that scenario.

What does it take to be nimble enough to design and test an updated vaccine against an unknown viral strain, in record time? Nature spoke to three COVID-19 vaccine makers — Pfizer, Moderna and AstraZeneca — to find out exactly how they are preparing.

DRESS REHEARSAL

Over the past few months, all three companies have been running dress rehearsals by practising on known SARS-CoV-2 variants. This involves updating their vaccines to match variants such as Beta and Delta, testing them in clinical studies, tuning their internal workflows and coordinating with regulators. Their goal is to learn from these warm-up trials and smooth out kinks in their processes, so that they can move fast if, or when, a true escape variant emerges.

“At some point, inevitably, we’re going to have to make variant vaccines — if vaccines are the way population immunity will be maintained — but we’re not at the point where we can confidently predict the evolution of the virus,” says Paul Bieniasz, a virologist at the Rockefeller University in New York City. “Practising with existing variants seems like a reasonable approach.”

The first generation of COVID-19 vaccines seems to be holding up against Delta and other known variants, at least in preventing severe disease and hospitalization. Pfizer, Moderna and AstraZeneca say that their vaccines, which are based on the original SARS-CoV-2 strain that was first detected in Wuhan, China, still offer the best protection against all known variants. “There really isn’t a need at this time to make a new vaccine that will be more effective, because it looks like the old ones work very well [against] the Delta variant,” says Kathryn Edwards, scientific director of the Vanderbilt Vaccine Research Program at Vanderbilt University Medical Center in Nashville, Tennessee.

If an escape variant emerges, RNA vaccine makers such as Pfizer and Moderna could probably design and synthesize an initial prototype jab against it in a few days. Viral-vector vaccines, such as AstraZeneca’s, could follow closely behind. Making an RNA vaccine typically involves generating a new genetic sequence and encapsulating it in a fatty substance such as a lipid. Viral-vector vaccines are generated by inserting the key genetic sequence into a harmless carrier virus, culturing large quantities of the virus in a bioreactor, and purifying them.

But before these shots can be deployed, they will have to be tested in humans, and that will take time. So pharma companies are doing dry runs. Pfizer, with its partner BioNTech, based in Mainz, Germany, is testing a Beta-specific RNA vaccine in a randomized, placebo-controlled clinical trial with up to 930 participants. In August, the companies began a trial of a multivalent vaccine that targets both the Delta and Alpha variants.

“We’re not doing that because we actually think we need a new vaccine for those strains,” says Philip Dormitzer, vice-president and chief scientific officer of viral vaccines and mRNA at Pfizer, based in New York City. “We want to practise all aspects of executing a strain change — the preclinical research, the manufacturing, the clinical testing and the regulatory submissions — so that if we do see a variant out there that truly escapes vaccine immunity, we’re ready to go fast.” Dormitzer says Pfizer currently has no plans to deploy its Beta or Delta vaccines among the public.

Moderna, based in Cambridge, Massachusetts, is recruiting cohorts of 300–500 participants to test new RNA vaccines against Beta, Delta and a combination of Beta and the original strain. The company also plans to test a Beta–Delta multivalent vaccine. The purpose is to submit test cases to the US Food and Drug Administration and “establish a process by which this could happen more quickly in the future”, says Jacqueline Miller, a senior vice-president and head of infectious-disease research at Moderna.

Beta is a particular focus because it carries mutations that make it more resistant than any other known variant to neutralization by antibodies created in a person’s body after they’ve been vaccinated. “If there’s another strain that evolves those mutations in the future, we can capitalize on what we’ve already learned from studying the Beta variant,” Miller says.

AstraZeneca, based in Cambridge, UK, has begun a large study of a Beta-specific viral-vector vaccine. Launched in June, the study is enrolling more than 2,800 participants, many of whom have already been vaccinated with either a messenger RNA vaccine or AstraZeneca’s first-generation viral-vector vaccine. “We’re definitely practising with this one, but we are also developing it, and if it’s successful, we will have it ready to use,” says Mene Pangalos, executive vice-president of biopharmaceuticals research and development at AstraZeneca.

REAL-WORLD EFFECTIVENESS

Determining the true efficacy of variant vaccines will be difficult. In regions where COVID-19 vaccine trials are well established, it can be hard to find volunteers who have not yet received a vaccine, yet are willing to enrol in an experimental trial of a new one. There might also be ethical concerns around recruiting placebo groups for randomized controlled trials, given that effective vaccines are available.

“If we’re not going to do randomized controlled trials for efficacy, one alternative would be to do immunogenicity studies, plus really robust, well-designed real-world effectiveness studies,” says Matthew Hepburn, who until August was the director of COVID-19 vaccine development at the US government’s Countermeasures Acceleration Group (formerly Operation Warp Speed) and is now a special adviser at the White House Office of Science and Technology Policy.

Immunogenicity studies would measure the immune responses triggered by variant vaccines — for instance, an increase in antibody or B-cell levels — and compare those with the effects of the first-generation vaccine. That seems to be where some vaccine makers are heading: on the basis of guidance from European regulators, AstraZeneca will use this approach in its Beta-vaccine trial.

Moderna is also focusing on immunogenicity data, and is collaborating with a hospital system in southern California to collect real-world data on vaccine effectiveness. In these observational studies, participants can choose whether they get a vaccine or not, and researchers monitor the two groups to see how they fare. Such studies “aren’t perfect”, concedes Miller, because the two groups might have different behaviours and risk factors.

How public-health authorities will determine that a variant has escaped — and therefore the world needs a new COVID-19 vaccine — isn’t yet clear. Pangalos offers one way to measure that: “If we start to see lots of people going into the hospital that have been vaccinated, then we have a problem,” he says. “But right now, we’re nowhere near that.”

The World Health Organization has a regimented process for determining when and how to change an influenza vaccine to match an emerging strain. These decisions are based in part on a long history of monitoring and immunizing against the virus’s evolution. “That doesn’t exist for COVID,” says Hepburn.

Miller hopes that the process of updating a COVID-19 vaccine will eventually become as streamlined as changing a flu vaccine, which typically doesn’t require much in the way of clinical studies. And because RNA vaccines can be manufactured more quickly than conventional jabs, she adds, “the idea would be to make that switch even more rapidly than we’re able to do with flu”.

https://www.scientificamerican.com/article/covid-vaccine-makers-prepare-for-a-variant-worse-than-delta/

Study: Nearly all severely allergic people tolerate COVID vaccines

 While healthcare workers at a Boston healthcare system with severe allergies reported more reactions after receiving a COVID-19 mRNA vaccine, nearly all were able to safely complete the series, according to an observational study yesterday in JAMA Network Open.

Researchers at Mass General Brigham and Harvard Medical School mined the electronic health records of 52,998 employees, of whom 97.6% received both doses of vaccine, and 0.9% reported a history of high-risk allergy. The study period was Dec 14, 2020, to Feb 1, 2021. Participants completed a prevaccination allergy risk assessment and at least one postvaccination symptom survey during the 3 days after vaccination.

Current contraindications to COVID-19 mRNA vaccination include a history of severe or immediate allergic reactions to any vaccine component or to a previous dose of an mRNA vaccine. The employees, however, were given the vaccine according to Centers for Disease Control and Prevention guidelines, allergist consultation, risk stratification, and shared decision-making.

Rate of severe reactions: 0.3%

Allergic symptoms emerged more often after the first rather than the second dose. Most symptoms were mild (eg, rash, itching), at 2.7%, but respiratory symptoms (1.3%), hives (0.9%), and angioedema (swelling of the face, lips, eyes, or tongue) (0.6%) were also reported.

Severe allergic reactions were rare (0.3%). Of the 140 participants who reported severe allergic symptoms after vaccination, 4.3% had a history of high-risk allergy. The risk of a severe allergic reaction after vaccination was 1.3% among workers with a high-risk allergy history and 0.3% among those who had never had a high-risk reaction.

Relative to workers without allergies, those with severe allergies had more reactions after receiving one or two vaccine doses (11.6% vs 4.7%). After adjustment, high-risk allergy was tied to increased risk of reactions (adjusted relative risk [aRR], 2.46; 95% confidence interval [CI], 1.92 to 3.16). Risks were highest for hives (aRR, 3.81; 95% CI, 2.33 to 6.22) and angioedema  (aRR, 4.36; 95% CI, 2.52 to 7.54).

"However, reported allergy symptoms did not impede the completion of the 2-dose vaccine protocol among a cohort of eligible health care employees, supporting the overall safety of mRNA COVID-19 vaccine," the study authors wrote.

Participants were, on average, 42 years old, and 72% were women. Women and Black participants made up much higher proportions of those with a history of severe allergy than those with no history of allergy (80.8% vs 71.9% and 9.5% vs 4.8%, respectively).

Severely allergic vaccinees were older than those with no allergy history (46 vs 42 years on average), had more atopic (allergic) skin conditions (16.7% vs 8.7%), anxiety (28.9% vs 23.9%), high blood pressure (14.6% vs 10.9%), and cancerous tumors (4.0% vs 2.4%).

Participants at highest risk of allergic reactions to the vaccine were Black (RR, 1.69), had a higher Charlson comorbidity index score (RR, 1.04), and received the Moderna rather than the Pfizer vaccine (RR, 1.49). Compared with women, men were at decreased risk for a reaction (RR, 0.66).

Among 474 employees with a history of severe allergy, 46.6% had a previous reaction to an unknown or known allergen (eg, food, venom, drug, latex). Nearly 46% of these workers reported a previous severe allergic reaction to an injectable medication or vaccine. Only 1.9% had a previous severe allergic reaction to polyethylene glycol (PEG) (an inert vaccine ingredient) or PEG-containing products (eg, Miralax, injectable steroid).

People with history of reactions should consult allergist

Soon after the US Food and Drug Association issued an emergency use authorization for the mRNA COVID-19 vaccines from Pfizer/BioNTech and Moderna in December 2020, several severe allergic reactions were reported, raising concerns about vaccine safety, the researchers noted.

Since then, the reported rate of allergic reactions to these vaccines has been about 2%, and anaphylaxis (a severe, potentially life-threatening allergic reaction) has been estimated to occur in 0.025 to 2.47 cases per 10,000 vaccinations—or a 0.02% risk on the high end of that range. Of vaccinees who experienced anaphylaxis after vaccination, about a third had a history of the reaction.

Whether severe allergies are linked to allergic reactions after mRNA vaccination is still unclear, the authors noted, because the observed reactions may not be true allergies. People with a history of severe allergy to PEG should consult their allergist or immunologist before seeking COVID-19 vaccination; such an allergy may not be a contraindication for vaccination.

"Identification of risk factors for allergy symptoms after COVID-19 vaccination will guide safe vaccination practices for individuals at the highest risk and inform strategies that target vaccine hesitancy that is associated with allergy concerns," the researchers wrote.

Overall, the results are reassuring for people who have a history of severe allergy, senior author Kimberly Blumenthal, MD, said in a Massachusetts General Hospital news release.

"We hope these data will help inform ongoing conversations with patients who are hesitant to receive COVID-19 vaccination due to allergy concerns," she said. "At our institutions, nearly all individuals with and without a history of high-risk allergy were able to complete the two-dose vaccine series."

https://www.cidrap.umn.edu/news-perspective/2021/10/study-nearly-all-severely-allergic-people-tolerate-covid-vaccines

Texas abortion numbers dropped 50 percent following ban

 The number of abortions in Texas fell by nearly 50 percent after the state enacted its six-week abortion ban, according to a report from researchers at the University of Texas at Austin released Friday.

The report from the university’s Texas Policy Evaluation Project compared the changes in the number of in-state abortions that occurred between July and September 2021 to the number of abortions that were performed during the same period last year. 

There were 2,164 abortions performed in September 2021, the month after Texas Senate Bill 8 ban went into effect on Sept. 1. That is a 49.8 percent drop from the 4,313 abortions that were performed in September 2020.  

The bill effectively bans abortions once a fetal heartbeat is detected, which is usually around six weeks.

The law also allows private citizens to sue those who performed or “aided and abetted” in an abortion in violation of the law and allows plaintiffs to recover at least $10,000 for successful cases.

The Supreme Court is set to hear oral arguments on Nov. 1 in challenges to the law brought by abortion providers and the Department of Justice in an effort to block Texas from enforcing the bill. 

The researchers evaluated monthly data on the total number of abortions provided at 19 of the state’s 24 abortion facility, which collectively provide roughly 93 percent of abortions reported to the state.

According to the report, over 40 percent of people who seek abortion care do not contact a provider until after six weeks of pregnancy.

The data suggested that SB8’s narrow criteria excluded many pregnant people from obtaining abortions in Texas. However, the researchers said that there was early evidence that Texans are instead leaving the state to seek abortion care and straining capacity at out-of-state facilities.

Wait times for clinics at neighboring states — such as Oklahoma and New Mexico — were longer in September 2021 than they were in July 2020, when the most recent data was available. Wait times exceeding two weeks were common at some facilities, the report found.  

https://thehill.com/policy/healthcare/abortion/579251-texas-abortion-numbers-dropped-50-percent-following-ban

Tennessee legislature rolls back some COVID-19 rules

 During a special session that stretched into early Saturday morning, the Tennessee legislature approved a rollback on some COVID-19 protections while agreeing to allow the exception for others.

The Tennessee legislature passed a measure that would only allow mandating masks in certain situations. If a county reaches a rolling 14-day average of at least 1,000 cases per 100,000 people, public schools and government entities would be allowed to mandate masks, the Tennessean reported. No county has yet reached that threshold.

Correctional facilities and certain businesses such as private schools can still require masks, however. Airport authorities, government contractors, long-term care facilities and certain other businesses can also require masks.

Under the measures passed, people would also be able to collect unemployment if they left their job due to a COVID-19 vaccine requirement, according to the Tennessean.

Certain entities like health care providers that participate in Medicaid and Medicare programs and government contractors are allowed to require vaccines for their workers. Public universities that receive money from the government and successfully argue that they could lose out on federal funding can also require masks and vaccines.

The moves come as companies such as Ford Motor Co. raised their concerns over legislative actions that would negatively impact their businesses, the Tennessean noted.

Tennessee Gov. Bill Lee (R) did not say immediately what measures he would support, but he noted each piece was being evaluated.

“I commend members of the General Assembly for working to address the Biden Administration's overreach into our state, our workforce, & our schools. We are evaluating each piece of legislation to ensure we push back on harmful federal policies & do right by Tennesseans,” Lee said Saturday in a tweet.

https://thehill.com/homenews/state-watch/579258-tennessee-legislature-rolls-back-some-covid-19-protections